Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
The serum complement system, which represents a chief component of innate immunity, not only participates in inflammation but also acts to enhance the adaptive immune response. Specific activation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results